Home › Companies › REPL

Replimune Group, Inc.

REPL Lead: Phase 3 2 Biotech Distilled articles ↓

Oncology Gene Therapy

Most recent annual filing: 2025-05-15

Pipeline (4 active programs)

vusolimogene oderparepvec

RP1

Gene Therapy

Melanoma Phase 3 intratumoral Bristol Myers Squibb
Cutaneous Squamous Cell Carcinoma Phase 2 intratumoral Bristol Myers Squibb

RP2

Gene Therapy

Uveal Melanoma Phase 2 intratumoral Bristol Myers Squibb
Hepatocellular Carcinoma Phase 2 intratumoral Roche

Technology platforms

RPx

Proprietary oncolytic immunotherapy platform based on an engineered HSV-1 backbone with multiple immune-activating payloads (GALV-GP R(-), GM-CSF, anti-CTLA-4, CD40L, 4-1BBL); designed for intratumoral administration to induce local and systemic anti-tumor immunity; focus areas: skin cancers, liver cancers, uveal melanoma, and other solid tumors

Discontinued (1)

RP3 — undisclosed · program deprioritized; not pursuing further development at this time

Biotech Distilled coverage (2)

2026-04-10 UPDATE: Replimune (REPL) - The Hammer Drops 🔒 Paid
2026-02-17 Replimune (REPL): Scientific Deep Dive for RP1, RP2, and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.